JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumor-selective protein in prostate cancer cells Among patients with measurable disease in...
Hence then, the article about johnson johnson reports 75 tumor response rate in advanced prostate cancer with jnj 6143 a first in class riptac molecule was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule )
Also on site :
- Anthropic Sued for Using Elvis Presley Music to Train AI Models
- Cynthia Erivo Plays Glinda in ‘Nigerian Wicked’ Sketch on ‘SNL U.K.’: ‘She Wants a BBL That Defies Gravity’
- Trump: US could strike Iran on Sunday